Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas

[1]  T. Burns,et al.  Glioma Metabolic Feedback In Situ: A First-In-Human Pharmacodynamic Trial of Difluoromethylornithine + AMXT-1501 Through High-Molecular Weight Microdialysis. , 2023, Neurosurgery.

[2]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[3]  Xuemin Zhang,et al.  Suppression of mitochondrial ROS by prohibitin drives glioblastoma progression and therapeutic resistance , 2021, Nature Communications.

[4]  S. Heiland,et al.  Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas , 2021, Nature Cancer.

[5]  J. Xia,et al.  MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights , 2021, Nucleic Acids Res..

[6]  C. Kleinman,et al.  Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas , 2021, Nature Communications.

[7]  Y. Reshetnyak,et al.  Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma , 2021, Science Advances.

[8]  T. Bamba,et al.  Glioma cells require one-carbon metabolism to survive glutamine starvation , 2021, Acta neuropathologica communications.

[9]  H. Schwalbe,et al.  Non-Invasive Measurement of Drug and 2-HG Signals Using 19F and 1H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032 , 2020, Cancers.

[10]  C. Tufarelli,et al.  The Janus-like role of proline metabolism in cancer , 2020, Cell death discovery.

[11]  K. Nałęcz,et al.  Glioma cells survival depends both on fatty acid oxidation and on functional carnitine transport by SLC22A5 , 2020, Journal of neurochemistry.

[12]  C. Najac,et al.  MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma , 2020, Theranostics.

[13]  Wenzhi Sun,et al.  Using arterial–venous analysis to characterize cancer metabolic consumption in patients , 2020, Nature Communications.

[14]  Binu P. Thomas,et al.  Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness. , 2020, Neuro-oncology.

[15]  Jennie W. Taylor,et al.  Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. , 2020, JAMA oncology.

[16]  I. Mellinghoff,et al.  Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma , 2020, ACS medicinal chemistry letters.

[17]  Jiyeon Kim,et al.  Amino acids in cancer , 2020, Experimental & Molecular Medicine.

[18]  A. Bergenheim,et al.  Metabolic response patterns in brain microdialysis fluids and serum during interstitial cisplatin treatment of high-grade glioma , 2019, British Journal of Cancer.

[19]  P. Mischel,et al.  Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets , 2019, Nature Reviews Cancer.

[20]  R. Jain,et al.  The blood–brain barrier and blood–tumour barrier in brain tumours and metastases , 2019, Nature Reviews Cancer.

[21]  J. Locasale,et al.  Methionine metabolism in health and cancer: a nexus of diet and precision medicine , 2019, Nature Reviews Cancer.

[22]  Z. Wang,et al.  Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma , 2019, Proceedings of the National Academy of Sciences.

[23]  C. Mandal,et al.  Nutritional stress reprograms dedifferention in glioblastoma multiforme driven by PTEN/Wnt/Hedgehog axis: a stochastic model of cancer stem cells , 2018, Cell Death Discovery.

[24]  Deric M. Park,et al.  Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade , 2018, Neurosurgery.

[25]  Christian M. Metallo,et al.  Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma , 2018, Cell.

[26]  B. Rosen,et al.  Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate , 2018, Nature Communications.

[27]  O. Sampetrean,et al.  Metabolic heterogeneity and plasticity of glioma stem cells in a mouse glioblastoma model , 2018, Neuro-oncology.

[28]  A. Giordano,et al.  The carnitine system and cancer metabolic plasticity , 2018, Cell Death & Disease.

[29]  K. Hess,et al.  Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas , 2018, CNS oncology.

[30]  Leland S. Hu,et al.  Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data , 2018, Neuro-oncology.

[31]  Marie Strickland,et al.  Metabolic Reprogramming in Glioma , 2017, Front. Cell Dev. Biol..

[32]  Bifeng Yuan,et al.  Sensitive Determination of Onco-metabolites of D- and L-2-hydroxyglutarate Enantiomers by Chiral Derivatization Combined with Liquid Chromatography/Mass Spectrometry Analysis , 2015, Scientific Reports.

[33]  Y. Kondo,et al.  Epigenetic dysregulation in glioma , 2014, Cancer science.

[34]  P. Frankel,et al.  A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agent , 2014, Journal of Neuro-Oncology.

[35]  M. Pešić,et al.  Genomic instability and p53 alterations in patients with malignant glioma. , 2012, Experimental and molecular pathology.

[36]  Hong Wu,et al.  Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy , 2012, Journal of Neuro-Oncology.

[37]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[38]  John O. Prior,et al.  Performance of 18F-Fluoro-Ethyl-Tyrosine (18F-FET) PET for the Differential Diagnosis of Primary Brain Tumor: A Systematic Review and Metaanalysis , 2012, The Journal of Nuclear Medicine.

[39]  Heinrich Lanfermann,et al.  Multimodality Assessment of Brain Tumors and Tumor Recurrence , 2011, The Journal of Nuclear Medicine.

[40]  P. Mischel,et al.  Metabolic state of glioma stem cells and nontumorigenic cells , 2011, Proceedings of the National Academy of Sciences.

[41]  M. Tachikawa,et al.  Transport characteristics of guanidino compounds at the blood-brain barrier and blood-cerebrospinal fluid barrier: relevance to neural disorders , 2011, Fluids and Barriers of the CNS.

[42]  A. Bergenheim,et al.  Metabolomic patterns in glioblastoma and changes during radiotherapy: a clinical microdialysis study. , 2010, Journal of proteome research.

[43]  E. Want,et al.  Intra-operative, real-time, three-dimensional ultrasound assisted positioning of catheters in the microdialysis of glial tumours , 2010, Journal of Clinical Neuroscience.

[44]  H. Marcus,et al.  In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines , 2010, Journal of Neuro-Oncology.

[45]  N. Gordon.  Guanidinoacetate methyltransferase deficiency (GAMT) , 2010, Brain and Development.

[46]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[47]  Luc Taillandier,et al.  Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. , 2009, Neuro-oncology.

[48]  J. Moffett,et al.  N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology , 2007, Progress in Neurobiology.

[49]  N. Verhoeven,et al.  Measurement of urinary D- and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography-tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride. , 2004, Clinical chemistry.

[50]  M. Weller,et al.  Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death , 2003, Cell Death and Differentiation.

[51]  OUP accepted manuscript , 2022, Neuro-Oncology.

[52]  Hai Yan,et al.  Isocitrate dehydrogenase mutations in gliomas. , 2016, Neuro-oncology.

[53]  J. Olson,et al.  Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study , 2008, Journal of Neuro-Oncology.

[54]  M. Milburn,et al.  Metabolon, Inc. , 2007, Pharmacogenomics.

[55]  Koen Van Laere,et al.  Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value , 2004, European Journal of Nuclear Medicine and Molecular Imaging.